Efficacy and Safety of Iguratimod Supplement to the Standard Immunosuppressive Regimen in Highly Mismatched Renal Transplant Recipients: A Pilot Study.

Front Immunol · 2021 · PMC8650225 · PMID 34887851

Europe PMC DOI

hedged sentence

0.1900

closest p · 3.8× alpha

0.1900

boldest claim

The sentences

did not reach statistical significanceP = 0.19not close (p > 0.1)

In the IGU group, the overall one-year BPAR rate was 14.8% (4/27), which was lower than the 29.6% (8/27) observed in the control group, but the difference did not reach statistical significance (Pearson’s chi-squared P = 0.19).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.